Live Breaking News & Updates on Treatment resistant depression

Stay informed with the latest breaking news from Treatment resistant depression on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Treatment resistant depression and stay connected to the pulse of your community

Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression

/PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on developing next-generation...

United-states , Jannsen-spravato , Dina-burkitbayeva , David-hough , Smith-carls , John-krystal , Rob-berman , Us-dept-of-health , Biohaven-pharmaceuticals , National-survey-on-drug , Mental-health-services-administration , Freedom-biosciences-inc

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Berlin , Germany , Beckley-psytech , Life-sciences , Exchange-commission , Treatment-resistant , Treatment-resistant-depression , Florian-brand , Private-securities-litigation-reform-act ,

Hidradenitis Suppurativa Market is expected to Grow at a CAGR

Hidradenitis Suppurativa Market is expected to Grow at a CAGR
openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.

Italy , United-states , Spain , Germany , France , United-kingdom , Japan , Beckley-psytech , Celon-pharma , Navitor-pharmaceuticals , Novartis , Treatment-resistant-depression

Treatment Resistant Depression Market Size, Report

Treatment Resistant Depression Market Size, Report
openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.

Market-research , Treatment-resistant-depression ,

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next month NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical

Clinical-stage , Treatment-resistant-depression , Generalized-anxiety-disorder ,

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massachusetts , United-states , New-york , Garo-armen , Advisory-inc , Company-contact , Nasdaq , Protagenic-therapeutics-inc , Clinical-stage , Treatment-resistant-depression , Generalized-anxiety-disorder , Protagenic-therapeutics

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results ...

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results ...

Massachusetts , United-states , Garo-armen , News-network , Protagenic-therapeutics-inc , Nasdaq , Clinical-stage , Treatment-resistant-depression , Generalized-anxiety-disorder , Protagenic-therapeutics , Clinical-trial , Protocol-progress

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing

New-york , United-states , Massachusetts , Garo-armen , Nasdaq , Advisory-inc , Protagenic-therapeutics-inc , Company-contact , Clinical-stage , Treatment-resistant-depression , Generalized-anxiety-disorder , Protagenic-therapeutics

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the s...

Massachusetts , United-states , New-york , Garo-armen , Advisory-inc , Nasdaq , Company-contact , Protagenic-therapeutics-inc , Clinical-stage , Treatment-resistant-depression , Generalized-anxiety-disorder , Protagenic-therapeutics

5-MeO-DMT Study Shows Relief For Treatment-Resistant Depression

5-MeO-DMT used for depression for those who do not respond to traditional and first-line therapeutics; results show a rapid antidepressant response in 55% of patients.

Beckley-psytech , Cosmo-feilding-mellen , National-institutes-of-health , National-institutes , 5-meo-dmt , Trd , Treatment-resistant-depression , Mebufotenin , Ssri , Prozac ,